Jorge Romaguera

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang, Simon Rule, Peter Martin et al. · New England Journal of Medicine · 2013 · 1.7K citations · Full text

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Raoul Herbrecht, Jorge Romaguera, Gregor Verhoef et al. · Journal of Clinical Oncology · 2009 · 639 citations

High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

Jorge Romaguera, Luis Fayad, Maria Alma Rodriguez et al. · Journal of Clinical Oncology · 2005 · 557 citations · Full text

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Jason R. Westin, Fuliang Chu, Min Zhang et al. · The Lancet Oncology · 2013 · 528 citations · Full text

Lymphoid Neoplasia, Medicine, Immunology +10

Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

André Goy, Anas Younes, Peter McLaughlin et al. · Journal of Clinical Oncology · 2004 · 526 citations · Full text